Patients With Cancer Speak Up About the Types of Independence They Lost Because of Their Disease

October 4th 2022

By Sailaja Darisipudi

FDA Fast Tracks Investigational Drug for Potential Approval in Lung Cancer Subtype

October 4th 2022

By Ryan McDonald

Treatment with an investigational drug elicited a median progression-free survival (time from treatment until disease progression or death) of 8.9 months among patients with a form of unresectable or metastatic squamous non-small cell lung cancer, according to trial findings.

It Helps to Have a Beautiful Center for Cancer Treatments

October 4th 2022

By Jane Biehl Ph.D.

Of course, I want the best cancer care, but I realized that the beauty of the environment where I get it is important too.

Rubraca Lengthens Time to Progression in Metastatic Prostate Cancer

October 4th 2022

By Brielle Benyon

Men with metastatic castration-resistant prostate cancer lived longer without their disease progressing when treated with Rubraca compared to standard of care.

My Body Was Hijacked by Cancer, So I Must ‘Dig in Deep and Fight’

October 4th 2022

My healthy body was hijacked by an enemy (ovarian cancer) launching my continuous fight against the disease.